Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded to “Sell” at BidaskClub

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Tuesday, BidAskClub reports.

CPRX has been the subject of a number of other research reports. Oppenheimer reiterated a “buy” rating and set a $8.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Tuesday, August 4th. ValuEngine upgraded Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, July 24th. Piper Sandler cut their price objective on Catalyst Pharmaceuticals from $7.00 to $6.00 in a research report on Tuesday, August 11th. Finally, Roth Capital reissued a “buy” rating on shares of Catalyst Pharmaceuticals in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $8.67.

Shares of NASDAQ:CPRX opened at $3.42 on Tuesday. Catalyst Pharmaceuticals has a one year low of $2.55 and a one year high of $6.75. The stock has a fifty day moving average of $3.59 and a 200-day moving average of $4.16. The company has a market capitalization of $353.84 million, a PE ratio of 8.77 and a beta of 1.54.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.01. Catalyst Pharmaceuticals had a return on equity of 44.37% and a net margin of 34.87%. The company had revenue of $29.61 million during the quarter, compared to the consensus estimate of $28.97 million. As a group, research analysts expect that Catalyst Pharmaceuticals will post 0.4 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in CPRX. Sawgrass Asset Management LLC acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at $50,000. Meeder Asset Management Inc. increased its stake in shares of Catalyst Pharmaceuticals by 111.8% in the first quarter. Meeder Asset Management Inc. now owns 13,747 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 7,255 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter worth $61,000. Jane Street Group LLC acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter worth $65,000. Finally, Arizona State Retirement System acquired a new position in shares of Catalyst Pharmaceuticals in the first quarter worth $84,000. 62.56% of the stock is currently owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Story: Do equity income investments outperform growth and income investments?

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.